Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
WST • Stock • Health Care / Health Care Supplies
Current Price
$364.98
-0.01%
Provider quote snapshot • As of 2026-10-02T20:00:00.000Z
Back to stock pageCross-Horizon Read
WST's evidence points supportive across the available windows.
Generated 2026-10-05T11:20:00.000Z • Evidence edf1da55
Price Data
A quote snapshot is available, but historical price data is not connected yet.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
6
Opposing articles
0
Neutral articles
9
Confidence basis
Supporting evidence
• West Pharmaceutical (WST) Upgraded to Buy: Here's Why
• WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
• Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2
• WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
• West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
Opposing evidence
No opposing articles were found in this window.
Catalysts
• West Pharmaceutical (WST) Upgraded to Buy: Here's Why
• Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
• WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
• West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03
• Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?
Risks
• Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
• WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
• WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (6) grows relative to opposing evidence (0) in this window.
• The most recent evidence in this window is not very fresh is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (6) in this window.
Showing 8 of 15 sources
West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative
Yahoo • 2026-08-20 • Mixed
Open via Finnhub →WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
Yahoo • 2026-08-14 • Bullish
Open via Finnhub →Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
Yahoo • 2026-08-13 • Mixed
Open via Finnhub →WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
Yahoo • 2026-08-13 • Mixed
Open via Finnhub →WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
Yahoo • 2026-08-13 • Mixed
Open via Finnhub →Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2
Yahoo • 2026-08-06 • Bullish
Open via Finnhub →West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03
Fintel • 2026-08-04 • Neutral
Open via Finnhub →